# ENTADFI® (finasteride-tadalafil) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/finasteride-tadalafil

> The FDA approved ENTADFI® (finasteride-tadalafil), sponsored by VERU INC. (VERU), on April 19, 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is ENTADFI® (finasteride-tadalafil) FDA approved?

Yes. The FDA approved ENTADFI® (finasteride-tadalafil), sponsored by VERU INC. (VERU), on April 19, 2023. SEC Form 10-Q: "On April 19, 2023, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") to sell substantially all of the assets related to ENTADFI® (finasteride and tadalafil) capsules for oral use, a new treatment for benign prostatic hyperplasia that was approved by the FDA in December 2021, with ONCO." [Calendar and source filings](https://sec-api.dev/pdufa/finasteride-tadalafil)

Source: SEC Form 10-Q, accession 0001437749-26-026664, https://www.sec.gov/Archives/edgar/data/863894/000143774926026664/veru20260630_10q.htm (retrieved 2026-11-12). Last confirmed 2026-08-10. Cite: https://sec-api.dev/pdufa/finasteride-tadalafil#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | ENTADFI® (finasteride-tadalafil) |
| Codes |  |
| Sponsor | VERU INC. (VERU) https://sec-api.dev/companies/veru/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### April 19, 2023: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2024-12-16, last confirmed 2026-08-10.
- SEC Form 10-Q (accession 0001437749-26-026664): "On April 19, 2023, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") to sell substantially all of the assets related to ENTADFI® (finasteride and tadalafil) capsules for oral use, a new treatment for benign prostatic hyperplasia that was approved by the FDA in December 2021, with ONCO." https://www.sec.gov/Archives/edgar/data/863894/000143774926026664/veru20260630_10q.htm
- SEC Form 10-Q (accession 0001437749-26-016557): "On April 19, 2023, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") to sell substantially all of the assets related to ENTADFI® (finasteride and tadalafil) capsules for oral use, a new treatment for benign prostatic hyperplasia that was approved by the FDA in December 2021, with ONCO." https://www.sec.gov/Archives/edgar/data/863894/000143774926016557/veru20260331_10q.htm
- SEC Form 10-Q (accession 0001437749-26-003725): "On April 19, 2023, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") to sell substantially all of the assets related to ENTADFI® (finasteride and tadalafil) capsules for oral use, a new treatment for benign prostatic hyperplasia that was approved by the FDA in December 2021, with ONCO." https://www.sec.gov/Archives/edgar/data/863894/000143774926003725/veru20251231_10q.htm
- SEC Form 10-K (accession 0001437749-25-038089): "On April 19, 2023, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") to sell substantially all of the assets related to ENTADFI® (finasteride and tadalafil) capsules for oral use, a new treatment for benign prostatic hyperplasia that was approved by the FDA in December 2021, with ONCO." https://www.sec.gov/Archives/edgar/data/863894/000143774925038089/veru20250930_10k.htm
- SEC Form 10-Q (accession 0001437749-25-026072): "On April 19, 2023, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") to sell substantially all of the assets related to ENTADFI® (finasteride and tadalafil) capsules for oral use, a new treatment for benign prostatic hyperplasia that was approved by the FDA in December 2021, with ONCO." https://www.sec.gov/Archives/edgar/data/863894/000143774925026072/veru20250630_10q.htm
- SEC Form 10-Q (accession 0001437749-25-015330): "On April 19, 2023, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") to sell substantially all of the assets related to ENTADFI® (finasteride and tadalafil) capsules for oral use, a new treatment for benign prostatic hyperplasia that was approved by the FDA in December 2021, with ONCO." https://www.sec.gov/Archives/edgar/data/863894/000143774925015330/veru20250331_10q.htm
- SEC Form 10-Q (accession 0001437749-25-003734): "On April 19, 2023, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") to sell substantially all of the assets related to ENTADFI® (finasteride and tadalafil) capsules for oral use, a new treatment for benign prostatic hyperplasia that was approved by the FDA in December 2021, with ONCO." https://www.sec.gov/Archives/edgar/data/863894/000143774925003734/veru20241231_10q.htm
- SEC Form 10-K (accession 0001437749-24-037576): "On April 19, 2023, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") to sell substantially all of the assets related to ENTADFI® (finasteride and tadalafil) capsules for oral use, a new treatment for benign prostatic hyperplasia that was approved by the FDA in December 2021, with ONCO." https://www.sec.gov/Archives/edgar/data/863894/000143774924037576/veru20240930_10k.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/finasteride-tadalafil.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ENTADFI® (finasteride-tadalafil) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/finasteride-tadalafil

```bibtex
@misc{secapidev_pdufa_finasteride_tadalafil_20261116,
  title        = {ENTADFI® (finasteride-tadalafil) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/finasteride-tadalafil}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_finasteride_tadalafil_20261116","title":"ENTADFI® (finasteride-tadalafil) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/finasteride-tadalafil","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
